Company intelligence / Profile preview
New Path Molecular Research Ltd
Cambridge, England, United Kingdomnewpathmolecular.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
New Path Molecular Research is developing fully synthetic drug conjugates that target phosphatidylserine on cancer cells using defensin analogues. Their approach is genetic alteration agnostic and does not require internalization by the tumor cell, aiming to overcome limitations of conventional antibody-drug conjugates. The company also applies advanced chemical synthesis techniques for complex molecule production, including lanthipeptides targeting drug-resistant bacteria and cancers. No published clinical results as of May 2025.[2][4][7]
- Therapeutic areas
- Oncology
- Modalities
- Synthetic drug conjugates (beyond ADCs)LanthipeptidesSmall proteins/defensin analogues[2][5][7]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on New Path Molecular Research Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on New Path Molecular Research Ltd.